Skip to content
Menu

Tenax Therapeutics, Inc. TENX

Full chart Compare
Set alert

Price alert · TENX

All alert types
1.25 USD -0.14 (-10.07%)

Regular-session close

1.24 -0.01 -0.78%

After hours · Nov 20, 6:29 PM ET

1.24 Day range 1.35
1.24 52-week range 19.40
YTD
-89.75%
1 year
-83.77%

5D -0.21 (-13.13%)

1.401.501.60FriMonTueWedThu1.39
Market cap
56.92M
EPS (ttm)
-1.39
Shares out
3.41M
Forward P/E
-1.06
YTD return
-89.75%
1-year return
-83.77%
50-day average
4.96
200-day average
3.94
Volume
2.28M
Avg volume
3.18M
Open
1.32
Previous close
1.39
Day's range
1.24 – 1.35
52-week range
1.24 – 19.40
Beta
2.15
Price target
16.30 (+1204.0%)

Key statistics

Enterprise value
7.73M
Price / book
0.20
Free cash flow
-7.55M
Total cash
9.38M
Total debt
278.80K
Return on equity
-113.79%
Short % of float
4.10%

Fundamental scorecard

6 of 25 checks passed on TENX’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TENX Revenue — quarterly 0
TENX Net income — quarterly -16.70M
TENX EPS — quarterly -0.31

Earnings

TENX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-1.38-0.19+1.19+86.23%
Aug 13, 2024Jun 1, 2024-1.99-1.83+0.16+8.04%
May 14, 2024Mar 1, 2024-2.40-3.12-0.72-30.00%
Apr 1, 2024Dec 1, 2023-8.15———
Nov 13, 2023Sep 1, 2023-7.20-6.40+0.80+11.11%
Aug 14, 2023Jun 1, 20230.00———

Upgrades / downgrades

TENX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 24, 2024Leerink Partnersinit—Outperform
Feb 20, 2024Roth MKMreitBuyBuy

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on TENX — it syncs with the Stock Master app.

Insider holders

TENX insider holders
InsiderRelationLatest transactionDateShares held
DAVIDSON MICHAEL HDirectorPurchaseAug 7, 20242,881
PROEHL GERALD TDirectorPurchaseAug 7, 20241,667

Institution ownership

TENX institution ownership
Holder% heldSharesValueReported
BVF Inc.9.96%339,5491.86MSep 29, 2024
Vivo Capital, LLC6.11%208,3331.14MSep 29, 2024
VR Adviser, LLC6.11%208,3331.14MSep 29, 2024
Velan Capital Investment Management LP2.44%83,333457.50KSep 29, 2024
Adage Capital Partners GP L.L.C.2.44%83,333457.50KSep 29, 2024
Vestal Point Capital, LP2.44%83,333457.50KSep 29, 2024

Fund ownership

TENX fund ownership
Holder% heldSharesValueReported
Price (T.Rowe) Health Sciences Fund0.78%26,472145.33KSep 29, 2024
Fidelity Extended Market Index Fund0.30%10,21756.09KOct 30, 2024
Fidelity Total Market Index Fund0.18%5,98432.85KOct 30, 2024
Fidelity Series Total Market Index Fund0.14%4,70825.85KOct 30, 2024
Vanguard Extended Market Index Fund0.07%2,32612.77KSep 29, 2024
Fidelity NASDAQ Composite Index Fund0.01%3642.00KOct 30, 2024